Latest Administration News

Wellnex Life has secured Therapeutic Goods Administration approval for its Liquid Paracetamol plus Caffeine Soft Gel, marking its fourth market authorisation and opening new revenue avenues.

Aeris Environmental has updated its quarterly cash flow report, confirming ongoing operational cash outflows but expressing confidence in maintaining current cash flow levels while exploring new funding avenues.

Janus Henderson Investors has announced the final distribution for its Sustainable Credit Active ETF, delivering 18.3819 cents per unit for January 2025. Key dates for investors include the ex-date on 3 February and payment on 13 February.

Alterity Therapeutics has raised over A$2 million through its U.S. ATM facility and expects nearly A$5.7 million in Australian tax rebates, fueling the advancement of its lead neurodegenerative drug candidate ATH434 following promising Phase 2 results.

Ten Sixty Four Limited has revealed a staggering net loss of US$43 million for the year ended June 2024, alongside a sharp 94% revenue decline and a modified audit opinion, raising fresh questions about its financial stability.

Dateline Resources Limited’s shares were suspended from ASX trading on 3 February 2025 due to a delayed periodic report, raising questions about compliance and future market activity.

Rewardle Holdings Limited reported a robust net cash inflow from operating activities of $3.98 million for Q4 2024, offsetting significant investing outflows and ending the quarter with $1.23 million in cash.

Savannah Goldfields Limited reported a net cash outflow in its December 2024 quarter, highlighting ongoing operational cash burn and a heavy reliance on loan facilities to sustain activities. The company’s liquidity position raises questions about its near-term funding strategy.

Australian Oil Company Limited (AOK) reports significant progress in its California pipeline acquisition and appoints Chris Hodge as Non-Executive Chairman, signaling a strategic push into US gas exploration.

Bridge SaaS Limited has recorded its first cashflow positive quarter, driven by strong growth at Brightside and strategic moves into the NDIS and DES sectors. The company is advancing plans for a tailored NDIS 'lite' SaaS offering aimed at smaller providers.

Argent BioPharma reports strategic cost-cutting moves including facility closures and delisting from the LSE, while securing German distribution approval and raising significant capital to support its drug pipeline.

AssetOwl Limited has appointed new directors and secured a $300,000 loan facility as it undertakes a strategic review to revive shareholder value amid a quiet quarter.